lidocaine has been researched along with Depression in 20 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
"This study evaluated the analgesic efficacy and emotional response to intravenous lidocaine infusion compared with placebo in patients with postherpetic neuralgia (PHN)." | 9.27 | The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. ( Li, J; Liu, H; Lu, F; Song, L; Xiao, H; Yang, B; Ye, L; Yin, Y; Zhou, D, 2018) |
" In this study, the efficacy of local lidocaine application on anxiety and depression and its curative effect in patients with chronic TTH was investigated." | 9.17 | Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. ( Inan, LE; Karadaş, Ö; Odabaşi, Z; Ulaş, Ü, 2013) |
"To assess the efficacy of 4% topical lidocaine in spheno-palatine blocks, a randomized controlled trial was carried out on patients with chronic muscle pain syndromes." | 9.08 | The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. ( Delaney, G; Heck, C; Janzen, V; McCain, GA; Russell, AL; Scudds, RA; Teasell, RW; Varkey, G; Woodbury, GM, 1995) |
"This study evaluated the analgesic efficacy and emotional response to intravenous lidocaine infusion compared with placebo in patients with postherpetic neuralgia (PHN)." | 5.27 | The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study. ( Li, J; Liu, H; Lu, F; Song, L; Xiao, H; Yang, B; Ye, L; Yin, Y; Zhou, D, 2018) |
" In this study, the efficacy of local lidocaine application on anxiety and depression and its curative effect in patients with chronic TTH was investigated." | 5.17 | Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. ( Inan, LE; Karadaş, Ö; Odabaşi, Z; Ulaş, Ü, 2013) |
"These data show that cerebral protection by lidocaine, which is unrelated to any effect on depression or anxiety, and is at a level that is noticed by the patients." | 5.09 | Cerebral protection by lidocaine during cardiac operations. ( Gorman, DF; Mitchell, SJ; Pellett, O, 1999) |
"To assess the efficacy of 4% topical lidocaine in spheno-palatine blocks, a randomized controlled trial was carried out on patients with chronic muscle pain syndromes." | 5.08 | The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. ( Delaney, G; Heck, C; Janzen, V; McCain, GA; Russell, AL; Scudds, RA; Teasell, RW; Varkey, G; Woodbury, GM, 1995) |
"The impact of an outpatient, risk-management system, including a transtelephonic electrocardiographic monitor and lidocaine injector, on the quality of life in post-myocardial infarction patients was examined." | 5.06 | Quality of life post-myocardial infarction: effects of a transtelephonic coronary intervention system. ( Capone, RJ; Follick, MJ; Gorkin, L; Smith, TW; Stablein, D; Visco, J, 1988) |
" Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
"Provoked vestibulodynia (PVD) is a highly prevalent and debilitating condition yet its management relies mainly on non-empirically validated interventions." | 2.82 | Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods. ( Bergeron, S; Dubois, MF; Dumoulin, C; Khalifé, S; Mayrand, MH; Morin, M; Waddell, G, 2016) |
"Patients with CRPS type I were treated with standardized pharmacological and physical therapy and were randomized to either TSB or control procedure as an add-on treatment." | 2.79 | Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study. ( Cantara, MG; de Andrade, DC; Faria, VG; Liggieri, V; Loduca, A; Müller, BM; Rocha, Rde O; Souza, AC; Teixeira, MJ; Yeng, LT, 2014) |
"We tested the hypothesis that ulcerative colitis-like inflammation induced by dextran sodium sulfate (DSS) exacerbates the ongoing spontaneous activity in colon-projecting afferent neurons that induces abdominal discomfort and anxiety, and depressive-like behaviors in rats." | 1.42 | Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation. ( Chen, J; Fu, Y; Green, TA; Guptarak, J; Jensen, KL; Sarna, SK; Shi, XZ; Winston, JH, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (15.00) | 18.7374 |
1990's | 2 (10.00) | 18.2507 |
2000's | 2 (10.00) | 29.6817 |
2010's | 12 (60.00) | 24.3611 |
2020's | 1 (5.00) | 2.80 |
Authors | Studies |
---|---|
Vivier, D | 1 |
Bennis, K | 1 |
Lesage, F | 1 |
Ducki, S | 1 |
Tripathi, SJ | 1 |
Chakraborty, S | 1 |
Rao, BSS | 1 |
Ji, NN | 1 |
Kang, J | 1 |
Hua, R | 1 |
Zhang, YM | 1 |
Liu, H | 1 |
Lu, F | 1 |
Zhou, D | 1 |
Yin, Y | 1 |
Li, J | 1 |
Yang, B | 1 |
Song, L | 1 |
Ye, L | 1 |
Xiao, H | 1 |
Karadaş, Ö | 1 |
Inan, LE | 1 |
Ulaş, Ü | 1 |
Odabaşi, Z | 1 |
Atalay, NS | 1 |
Sahin, F | 1 |
Atalay, A | 1 |
Akkaya, N | 1 |
Rocha, Rde O | 1 |
Teixeira, MJ | 1 |
Yeng, LT | 1 |
Cantara, MG | 1 |
Faria, VG | 1 |
Liggieri, V | 1 |
Loduca, A | 1 |
Müller, BM | 1 |
Souza, AC | 1 |
de Andrade, DC | 1 |
Chen, J | 1 |
Winston, JH | 1 |
Fu, Y | 1 |
Guptarak, J | 1 |
Jensen, KL | 1 |
Shi, XZ | 1 |
Green, TA | 1 |
Sarna, SK | 1 |
Laurent, B | 1 |
Vicaut, E | 1 |
Leplège, A | 1 |
Bloch, K | 1 |
Leutenegger, E | 1 |
Morin, M | 1 |
Dumoulin, C | 1 |
Bergeron, S | 1 |
Mayrand, MH | 1 |
Khalifé, S | 1 |
Waddell, G | 1 |
Dubois, MF | 1 |
Hikiji, W | 1 |
Kudo, K | 1 |
Nishida, N | 1 |
Ishida, T | 1 |
Usumoto, Y | 1 |
Tsuji, A | 1 |
Ikeda, N | 1 |
Abernethy, AP | 1 |
Farrell, TW | 1 |
Ay, S | 1 |
Evcik, D | 1 |
Tur, BS | 1 |
Trevino, K | 1 |
McClintock, SM | 1 |
Husain, MM | 1 |
Berger, A | 1 |
Sadosky, A | 1 |
Dukes, E | 1 |
Edelsberg, J | 1 |
Oster, G | 1 |
CRONHOLM, B | 2 |
OTTOSSON, JO | 2 |
Scudds, RA | 1 |
Janzen, V | 1 |
Delaney, G | 1 |
Heck, C | 1 |
McCain, GA | 1 |
Russell, AL | 1 |
Teasell, RW | 1 |
Varkey, G | 1 |
Woodbury, GM | 1 |
Mitchell, SJ | 1 |
Pellett, O | 1 |
Gorman, DF | 1 |
Follick, MJ | 1 |
Gorkin, L | 1 |
Smith, TW | 1 |
Capone, RJ | 1 |
Visco, J | 1 |
Stablein, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Sympathetic Ganglion Block in Patients With Chronic Upper Extremity Neuropathic Pain: a Prospective Randomized and Comparative Clinical Trial[NCT06130514] | 118 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | |||
Efficacy of Treatments for Provoked Vestivulodynia : a Randomised Clinical Trial Comparing Multimodal Physiotherapy Treatments to Topical Lidocaine[NCT01455350] | 212 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone[NCT03028012] | Phase 4 | 10 participants (Actual) | Interventional | 2017-05-02 | Terminated (stopped due to Poor enrollment.) | ||
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial.[NCT04704297] | Phase 4 | 180 participants (Anticipated) | Interventional | 2020-12-28 | Recruiting | ||
Comparative Study, Between Dry Needling Techniques, in the Evolution of Myofascial Pain Shoulder in Athletes. Elastography as Indicator in the Repair of Myofascial Tissue, Post-dry Needling.[NCT02889991] | 77 participants (Actual) | Interventional | 2016-05-02 | Completed | |||
Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011] | 3 participants (Actual) | Observational | 2020-01-10 | Terminated (stopped due to PI request - low enrollment) | |||
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain, one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Post Injections Up to Three Months
Intervention | Participants (Count of Participants) |
---|---|
Ketorolac | 1 |
Lidocaine | 0 |
Dexamethasone | 0 |
The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months. (NCT03028012)
Timeframe: Baseline and Three Months
Intervention | score on a scale (Number) | |||
---|---|---|---|---|
Participant Number #3 at Baseline | Participant Number #3 at 3 Months | Participant Number #8 at Baseline | Participant #8 at 3 Months | |
Ketorolac | 8 | 3 | 5 | 3 |
TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain,one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Injection and Three Month Post Injection(s)
Intervention | score on a scale (Number) | |||
---|---|---|---|---|
Participant Number 3 at Baseline | Participant Number 3 at 3 Months | Participant Number 8 at Baseline | Participant Number 8 at 3 Months | |
Ketorolac | 8 | 3 | 5 | 3 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
2 reviews available for lidocaine and Depression
Article | Year |
---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
8 trials available for lidocaine and Depression
Article | Year |
---|---|
The Analgesic and Emotional Response to Intravenous Lidocaine Infusion in the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blinded, Placebo-controlled Study.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Anxiety; Depression; Double-Blind Method; Emotio | 2018 |
Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache.
Topics: Adult; Anesthetics, Local; Anxiety; Depression; Double-Blind Method; Female; Humans; Injections; Lid | 2013 |
Thoracic sympathetic block for the treatment of complex regional pain syndrome type I: a double-blind randomized controlled study.
Topics: Adult; Anesthetics, Local; Depression; Disability Evaluation; Double-Blind Method; Female; Follow-Up | 2014 |
Randomized clinical trial of multimodal physiotherapy treatment compared to overnight lidocaine ointment in women with provoked vestibulodynia: Design and methods.
Topics: Academic Medical Centers; Administration, Topical; Adult; Anesthetics, Local; Anxiety; Catastrophiza | 2016 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial.
Topics: Adult; Anesthetics, Local; Depression; Female; Humans; Injections, Intramuscular; Lidocaine; Male; M | 2010 |
The use of topical 4% lidocaine in spheno-palatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial.
Topics: Administration, Topical; Adult; Anxiety; Autonomic Nerve Block; Chronic Disease; Depression; Double- | 1995 |
Cerebral protection by lidocaine during cardiac operations.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Anxiety; Brain Diseases; Depression; Double-Blind Method; Femal | 1999 |
Quality of life post-myocardial infarction: effects of a transtelephonic coronary intervention system.
Topics: Depression; Electrocardiography; Employment; Female; Humans; Interpersonal Relations; Lidocaine; Mal | 1988 |
10 other studies available for lidocaine and Depression
Article | Year |
---|---|
Remediation of chronic immobilization stress-induced negative affective behaviors and altered metabolism of monoamines in the prefrontal cortex by inactivation of basolateral amygdala.
Topics: Animals; Anxiety; Basolateral Nuclear Complex; Behavior, Animal; Biogenic Monoamines; Depression; Ib | 2020 |
Involvement of dopamine system in the regulation of the brain corticotropin-releasing hormone in paraventricular nucleus in a rat model of chronic visceral pain.
Topics: Animals; Animals, Newborn; Central Nervous System Agents; Chronic Pain; Corticotropin-Releasing Horm | 2018 |
Comparison of efficacy of neural therapy and physical therapy in chronic low back pain.
Topics: Activities of Daily Living; Adult; Anxiety; Depression; Disability Evaluation; Female; Humans; Injec | 2013 |
Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation.
Topics: Abdominal Pain; Action Potentials; Anesthetics, Local; Animals; Anxiety; Behavior, Animal; Colitis, | 2015 |
Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: the ZOCAD study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics; Anesthetics, Local; Anticonvu | 2014 |
Acute fatal poisoning with pilsicainide and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Chromatography, High Pressure Liquid; Depression; Fema | 2008 |
The use of topical lidocaine to reduce pain during repetitive transcranial magnetic stimulation for the treatment of depression.
Topics: Adult; Aged; Anesthetics, Local; Depression; Female; Humans; Lidocaine; Male; Middle Aged; Pain; Tra | 2011 |
Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Stero | 2012 |
Experimental studies of the therapeutic action of electroconvulsive therapy in endogenous depression. The role of the electrical stimulation and of the seizure studied by variation of stimulus intensity and modification by lidocaine of seizure discharge.
Topics: Convulsive Therapy; Depression; Depressive Disorder; Electric Stimulation; Electroconvulsive Therapy | 1960 |
ULTRABRIEF STIMULUS TECHNIQUE IN ELECTROCONVULSIVE THERAPY. I. INFLUENCE ON RETROGRADE AMNESIA OF TREATMENTS WITH THE ELTHER ES ELECTROSCHOCK APPARATUS, SIEMENS KONVULSATOR III AND OF LIDOCAINE-MODIFIED TREATMENT.
Topics: Amnesia; Amnesia, Retrograde; Depression; Depressive Disorder; Electroconvulsive Therapy; Humans; Li | 1963 |